Applied DNA Sciences, Inc.
APDN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $1 | $1 | $1 |
| % Growth | -69% | -17.8% | 47.2% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | 1.7% | 37.7% | 57.2% | 30.1% |
| R&D Expenses | $1 | $1 | $1 | $1 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $4 | $4 | $4 | $4 |
| Operating Income | -$4 | -$3 | -$3 | -$3 |
| % Margin | -1,213.6% | -352% | -247.7% | -402.3% |
| Other Income/Exp. Net | $0 | $0 | $0 | -$0 |
| Pre-Tax Income | -$4 | -$3 | -$3 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$27 | -$3 | -$3 |
| % Margin | -1,296.1% | -2,768.4% | -220.6% | -405.5% |
| EPS | -34 | -15.35 | -0.56 | -0.19 |
| % Growth | -121.5% | -2,641.1% | -194.7% | – |
| EPS Diluted | -34 | -15.35 | -0.56 | -0.19 |
| Weighted Avg Shares Out | 1 | 2 | 32 | 18 |
| Weighted Avg Shares Out Dil | 1 | 2 | 32 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$3 | -$3 | -$3 |
| % Margin | -1,187.8% | -327.2% | -242.8% | -392.8% |